ASMBS: More Than Nine in 10 Adults With Severe Obesity Receive No Treatment

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, May 8, 2026 -- Despite a sharp uptick in the use of glucagon-like peptide-1 (GLP-1) receptor agonists, most U.S. adults with severe obesity do not receive treatment, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from May 3 to 7 in San Antonio.

Ruth Laverde, M.D., from the University of California San Diego, and colleagues examined trends in bariatric surgery and GLP-1 receptor agonist use among adults with severe obesity (body mass index ≥35 kg/m2) without diabetes using electronic health record data (Epic Cosmos; 2016 through 2024), representing nearly 34.2 million U.S. patients.

The researchers found that bariatric surgery rates rose steadily, from 0.03 percent in 2016 to 0.24 percent in 2023, with a slight downtrend to 0.21 percent seen in 2024. Simultaneously, GLP-1 receptor agonist use steadily increased, from 0.03 percent (with a sharp increase after 2022) to 5.3 percent in 2024. This translated to an increase from fewer than 4,600 prescriptions in 2018 to more than 1.4 million in 2025. However, 94.4 percent of patients with severe obesity received no treatment.

"Undertreatment of obesity in the U.S. is well-known, but seeing the magnitude in this database is striking -- tens of millions untreated despite multiple effective therapies," Laverde said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-09 09:32

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords